SKYE

Skye Bioscience, Inc. (SKYE) Business Model Analysis (2026)

Invetso Score: 3.1/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Value Proposition Revenue Model

Score: 3.2 (Weak)

No operating revenue base: FMP shows zero capex-to-revenue and zero asset turnover, indicating no observable commercial revenue engine to assess.

No visible monetization structure: The available metrics do not evidence recurring sales, pricing power, or customer-paid product delivery, limiting revenue visibility versus operating peers.

Business model remains unproven: Compared with revenue-generating peers, SKYE lacks a demonstrated value-capture mechanism that can support durable 2–5 year growth.

Cost Structure

Score:

Minimal disclosed operating intensity: Zero capex-to-revenue suggests a very light current cost base, but it also reflects limited operational scale rather than efficient cost leverage.

No evidence of scalable cost absorption: With no observable revenue base, fixed-cost dilution cannot be assessed, leaving margins structurally untested versus peers.

Cash conversion remains unclear: Negative capex-to-OCF and null FCF margin indicate the cost structure is not yet translating into measurable free cash generation.

Scalability Operating Leverage

Score:

No operating leverage visible: Asset turnover of zero implies the company is not yet using assets to generate sales, limiting scalability versus commercial-stage peers.

Scale economics are absent: Without revenue throughput, incremental growth cannot be shown to expand margins or improve unit economics.

Structural expansion path is unproven: The current metrics do not demonstrate a repeatable operating model that can scale predictably over multiple years.

Customer Structure Concentration

Score:

Customer base is not disclosed in the metrics: The provided data do not show customer diversification, contract breadth, or end-market spread, reducing structural visibility.

Concentration risk cannot be offset by scale: Because the company lacks a visible revenue base, any future customer concentration would likely have a larger impact than at diversified peers.

Peer comparability is limited: Unlike established peers with recurring customer cohorts, SKYE’s customer structure is not yet evidenced in the available operating data.

Revenue Quality Predictability

Score:

Revenue quality is not evidenced: Null FCF margin and negative income quality indicate weak conversion from accounting inputs to cash-based performance.

Predictability is structurally low: Without demonstrated recurring revenue or asset productivity, future results are likely less repeatable than at mature peers.

Visibility is constrained: The available metrics provide no support for stable multi-year revenue or margin forecasting.

Overall Score

Score:

SKYE’s main structural limitation is the absence of an evidenced operating revenue model, while its only visible strength is a currently light cost base.

Score Driver: The Score Is Anchored By The Lack Of Observable Revenue Generation And Asset Productivity, Which Outweighs The Limited Evidence Of Low Capital Intensity.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Skye Bioscience, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →